You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
The company's CRISPR-chrom technology fuses chromatin-modulating peptides to CRISPR nucleases, essentially moving chromatin out of the way for more efficient editing.
Promega said it plans to use the technology to create new research products for investigating endogenous biology.
As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.
The Broad will now offer licenses for both its own CRISPR IP and MilliporeSigma's to companies using CRISPR in their research and development activities.
The firms originally inked the agreement in 2015 and have now extended it until 2025.
The deal is expected to close by the end of 2018 and to contribute between $40 million and $50 million in revenues to Luminex in 2019.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
Universities and research institutes are making CRISPR/Cas9 more accessible than ever through new and existing core facilities.
Sales for the firm's life science segment jumped 25 percent year over year to €3.36 billion from €2.68 billion.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.